Amryt Pharma hail rocketing revenue growth 'we're a biotech that makes money - Joe Wiley, CEO, Amryt Pharma 00:00:00
Joe Wiley talks to Proactive London's Katie Pilbeam after reporting revenue growth of 14.6% for the third quarter after sales of its lipodystrophy treatment metreleptin soared 21.5%.